Defendant Name: FibroGen, Inc.

Defendant Type: Public Company
SIC Code: 9999
CUSIP: 31572Q80

Initial Case Details

Legal Case Name In the Matter of FibroGen, Inc.
First Document Date 05-Sep-2025
Initial Filing Format Administrative Action
File Number 3-22528
Allegation Type Issuer Reporting and Disclosure

Violations Alleged

Exchange Act
• Sec 10(b) + Rule 10b-5
Securities Act
• Sec 17(a)(2)

Resolutions

First Resolution Date 05-Sep-2025
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

33-11387 05-Sep-2025 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings, Pursuant to Section 8A of the Securities Act of 1933 and Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On September 5, 2025, the SEC instituted settled cease-and-desist proceedings against FibroGen, Inc., stating: "This matter involves false and/or materially misleading statements about the results of certain cardiovascular safety analyses of FibroGen’s then-primary drug candidate Roxadustat, a potential therapy for the treatment of anemia in patients with chronic kidney disease."

Related Actions:

SEC v. Kin-Hung Peony Yu
Kin-Hung Peony Yu